Publications by authors named "E Smyth"
Article Synopsis
- - The ESMO Clinical Practice Guidelines for oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC) were updated into Pan-Asian adapted (PAGA) guidelines to better address the needs of Asian patients.
- - A panel of experts from multiple Asian oncological societies collaborated to create these guidelines, focusing on scientific evidence rather than local treatment practices or drug availability.
- - The guidelines aim to standardize the management of oncogene-addicted mNSCLC across Asia, while acknowledging regional differences in screening, treatment resources, and drug reimbursement policies.
Mantle cell lymphoma (MCL) is a clinically heterogeneous B-cell neoplasm with unique clinicopathological features, accounting for 5% of all non-Hodgkin lymphoma. Although for many chemoimmunotherapy can lead to durable remissions, those with poor baseline prognostic factors, namely blastoid morphology, TP53 aberrancy and Ki67 >30%, will have less durable responses to conventional therapies. With this in mind, clinical trials have focused on novel targeted therapies to improve outcomes.
View Article and Find Full Text PDFBackground: Patients with gastro-oesophageal adenocarcinoma with tumour-positive lymph nodes (ypN+) or positive surgical margins (R1) following neoadjuvant chemotherapy and resection are at high risk of recurrence. Adjuvant nivolumab is effective in oesophageal/oesophagogastric junction cancer and residual pathological disease following chemoradiation and surgery. Immune checkpoint inhibition has shown efficacy in advanced gastro-oesophageal cancer.
View Article and Find Full Text PDFBackground: High expression of programmed death-ligand 1 (PD-L1) has been recognized as a marker of improved efficacy of immunotherapy in gastroesophageal adenocarcinoma (GEA); however, the optimal PD-L1 cut-off is still debated. The aim of the present review was to analyze available phase III trials and to identify the appropriate PD-L1 expression cut-off for GEA.
Methods: Phase III trials investigating the efficacy of anti-programmed cell death protein 1 (PD-1) therapies in addition to standard chemotherapy versus standard chemotherapy in the first-line setting were selected.